Mark A. Dickson, MD, on Advanced Dedifferentiated Liposarcoma: SARC041 Trial

June 01, 2026 By The ASCO Post Staff

Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated liposarcoma; patients who received abemaciclib experienced a statistically significant improvement in progression-free survival (Abstract LBA2).

Related Content